Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Posted by Casey Walker on Feb 26th, 2025

Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 0.4 %

Shares of EVOK opened at $4.82 on Monday. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.32. The company has a market capitalization of $7.16 million, a PE ratio of -0.44 and a beta of 0.16. The stock has a fifty day simple moving average of $4.73 and a two-hundred day simple moving average of $4.81.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.